BACKGROUND: We retrospectively examined outcomes of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for locally recurrent rectal cancer (LRRC). METHODS: Nine patients with LRRC were treated with salvage HDR-ISBT. Their median age was 63 years. The median maximum diameter of LRRC was 40 mm (range 20-80 mm). Adenocarcinomas were histologically confirmed in all cases. The prescribed dose was 30 Gy/5 fractions/3 days to 50 Gy/10 fractions/6 days in the combined external-beam radiotherapy group (four patients) and 54 Gy/9 fractions/5 days to 60 Gy/10 fractions/6 days in the monotherapeutic group (five patients). Median follow-up time was 90 months (range 6-221 months). RESULTS: Local control at final follow-up was achieved in five of nine patients. Of these five patients, one experienced a locally re-recurrent tumor in the vaginal wall 33 months after treatment and received re-HDR-ISBT as re-salvage treatment. The 8-year overall survival, local control, and progression-free survival rates were 56, 44, and 33 %, respectively. Based on the Common Terminology Criteria for Adverse Events ver. 4.03, the following Grade 3 adverse events were observed in three patients (≥3 months): Grade 3 skin ulceration in one patient who showed tumor invasion of the skin and whose V100 was 400 cc; Grade 3 vaginal perforation in one patient whose tumor had invaded the vaginal wall; and Grade 3 vagina-to-bladder fistula in one patient whose tumor received re-irradiation. Late adverse events above Grade 3 were not observed. CONCLUSIONS: Long-term follow-up results revealed that salvage HDR-ISBT is a promising treatment for LRRC with tolerable toxicity.
BACKGROUND: We retrospectively examined outcomes of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for locally recurrent rectal cancer (LRRC). METHODS: Nine patients with LRRC were treated with salvage HDR-ISBT. Their median age was 63 years. The median maximum diameter of LRRC was 40 mm (range 20-80 mm). Adenocarcinomas were histologically confirmed in all cases. The prescribed dose was 30 Gy/5 fractions/3 days to 50 Gy/10 fractions/6 days in the combined external-beam radiotherapy group (four patients) and 54 Gy/9 fractions/5 days to 60 Gy/10 fractions/6 days in the monotherapeutic group (five patients). Median follow-up time was 90 months (range 6-221 months). RESULTS: Local control at final follow-up was achieved in five of nine patients. Of these five patients, one experienced a locally re-recurrent tumor in the vaginal wall 33 months after treatment and received re-HDR-ISBT as re-salvage treatment. The 8-year overall survival, local control, and progression-free survival rates were 56, 44, and 33 %, respectively. Based on the Common Terminology Criteria for Adverse Events ver. 4.03, the following Grade 3 adverse events were observed in three patients (≥3 months): Grade 3 skin ulceration in one patient who showed tumor invasion of the skin and whose V100 was 400 cc; Grade 3 vaginal perforation in one patient whose tumor had invaded the vaginal wall; and Grade 3 vagina-to-bladder fistula in one patient whose tumor received re-irradiation. Late adverse events above Grade 3 were not observed. CONCLUSIONS: Long-term follow-up results revealed that salvage HDR-ISBT is a promising treatment for LRRC with tolerable toxicity.
Authors: Y Yoshioka; T Nose; K Yoshida; T Inoue; H Yamazaki; E Tanaka; H Shiomi; A Imai; S Nakamura; S Shimamoto; T Inoue Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: Nestor F Esnaola; Scott B Cantor; Margo L Johnson; Attiqa N Mirza; Alexander R Miller; Steven A Curley; Christopher H Crane; Charles S Cleeland; Nora A Janjan; John M Skibber Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: Dieter Hahnloser; Heidi Nelson; Leonard L Gunderson; Imran Hassan; Michael G Haddock; Michael J O'Connell; Stephen Cha; Daniel J Sargent; Alan Horgan Journal: Ann Surg Date: 2003-04 Impact factor: 12.969
Authors: C S Wong; B J Cummings; J D Brierley; C N Catton; M McLean; P Catton; Y Hao Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-15 Impact factor: 7.038
Authors: Mandy van den Brink; Anne M Stiggelbout; Wilbert B van den Hout; Job Kievit; Elma Klein Kranenbarg; Corrie A M Marijnen; Iris D Nagtegaal; Harm J T Rutten; Theo Wiggers; Cornelis J H van de Velde Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: Joo Ho Lee; Dae Yong Kim; Sun Young Kim; Ji Won Park; Hyo Seong Choi; Jae Hwan Oh; Hee Jin Chang; Tae Hyun Kim; Suk Won Park Journal: Radiat Oncol Date: 2011-05-20 Impact factor: 3.481